| Cas No.: | 1627603-21-7 |
| Chemical Name: | TAK-020 |
| Synonyms: | U3T5W003VP;TAK020;GTPL11730;compound 3 [PMID: 34448571];3-[1-[(3S)-1-prop-2-enoylpyrrolidin-3-yl]oxyisoquinolin-3-yl]-1,4-dihydro-1,2,4-triazol-5-one;3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-(1-(((3S)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-3-isoquinolinyl)-;Unii-U3T5W003VP;TAK-020 |
| SMILES: | O(C1C2C=CC=CC=2C=C(C2=NNC(N2)=O)N=1)[C@@H]1CN(C(C=C)=O)CC1 |
| Formula: | C18H17N5O3 |
| M.Wt: | 351.359283208847 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate. |
| References: | [1]. Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):12893-12902. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
